Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 10/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614515 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL614514 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL27419562 | 0.94 | SMN1; SMN2 (0.44) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL16289367 | 0.92 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15083313 | 0.92 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12405615 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13950543 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8070420 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13652724 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL11934305 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2CTSKNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AG (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4583926-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4308551-B1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AG (DE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024052550-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335462-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4308551-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Aktiengesellschaft (DE) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022194777-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-22 | — | — | WO | disclosed |
| EP-4059925-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| US-8940722-B2 | Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8940722-B2 | Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2015-01-27 | — | — | US | disclosed |
| US-20130123250-A1 | SPIRO (PIPERIDINE-4,2'-PYRROLIDINE)-1-(3,5-TRIFLUOROMETHYLPHENYL) METHYLCARBOXAMIDES AS NK1 TACHIKYNIN RECEPTOR ANTAGONISTS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2013-05-16 | — | — | US | disclosed |
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2013-02-28 | — | — | US | disclosed |
| US-8367692-B2 | Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethyl phenyl) methylcarboxamides as NK1 tachikynin receptor antagonists | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2013-02-05 | — | — | US | disclosed |
| US-8367692-B2 | Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethyl phenyl) methylcarboxamides as NK1 tachikynin receptor antagonists | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2013-02-05 | — | — | US | disclosed |
| US-8367692-B2 | Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethyl phenyl) methylcarboxamides as NK1 tachikynin receptor antagonists | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2013-02-05 | — | — | US | disclosed |
| EP-2300474-B1 | SPIRO (PIPERIDINE-4, 2 ' -PYRROLIDINE) -1- (3, 5- TRIFLUOROMETHYL PHENYL) METHYLCARBOXAMIDES AS NK1 TACHIKYNIN RECEPTOR ANTAGONISTS | GLAXO WELLCOME MFG PTE LTD (SG) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011107248-A1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | PHENEX PHARMACEUTICALS AG (DE) | 2011-09-09 | — | — | WO | disclosed |
| EP-2300474-A1 | SPIRO (PIPERIDINE-4, 2 ' -PYRROLIDINE) -1- (3, 5- TRIFLUOROMETHYL PHENYL) METHYLCARBOXAMIDES AS NK1 TACHIKYNIN RECEPTOR ANTAGONISTS | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2011-03-30 | — | — | EP | disclosed |
| US-20110053922-A1 | Spiro (Piperidine-4,2'-Pyrrolidine)-1-(3,5-Trifluoromethyl Phenyl) Methylcarboxamides As NK1 Tachikynin Receptor Antagonists | NERRE THERAPEUTICS LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2009133135-A1 | SPIRO (PIPERIDINE-4, 2 ' -PYRROLIDINE) -1- (3, 5- TRIFLUOROMETHYL PHENYL) METHYLCARBOXAMIDES AS NK1 TACHIKYNIN RECEPTOR ANTAGONISTS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | RORB, RORC, RORA | SMN1; SMN2 2997/4885CTSK 4632/4885NFKB1 308/4885 |
| US-20110053922-A1 | Spiro (Piperidine-4,2'-Pyrrolidine)-1-(3,5-Trifluoromethyl Phenyl) Methylcarboxamides As NK1 Tachikynin Receptor Antagonists | HRH4, TACR2, TACR1 | SMN1; SMN2 3709/4885CTSK 1177/4885NFKB1 1375/4885 |
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | CA13, CCR1, GALC | SMN1; SMN2 2305/4885CTSK 1944/4885NFKB1 3742/4885 |
| US-20130123250-A1 | SPIRO (PIPERIDINE-4,2'-PYRROLIDINE)-1-(3,5-TRIFLUOROMETHYLPHENYL) METHYLCARBOXAMIDES AS NK1 TACHIKYNIN RECEPTOR ANTAGONISTS | TACR2, TACR1, TAC3 | SMN1; SMN2 2809/4885CTSK 847/4885NFKB1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.